Key result
Targeting syndecan-4 inhibits pathological angiogenesis and VE-cadherin internalization in preclinical disease models.
Answers are grounded in this paper and cite their sources.
Objective: VEGFA (Vascular endothelial growth factor A) and its receptor VEGFR2 (vascular endothelial growth factor receptor 2) drive angiogenesis in several pathologies, including diabetic retinopathy, wet age-related macular degeneration, and cancer. Studies suggest roles for HSPGs (heparan sulfate proteoglycans) in this process, although the nature of this involvement remains elusive. Here, we set to establish the role of the HSPG SDC4 (syndecan-4) in pathological angiogenesis. Approach and Results: We report that angiogenesis is impaired in mice null for SDC4 in models of neovascular eye disease and tumor development. Our work demonstrates that SDC4 is the only SDC whose gene expression is upregulated during pathological angiogenesis and is selectively enriched on immature vessels in retinas from diabetic retinopathy patients. Combining in vivo and tissue culture models, we identified SDC4 as a downstream mediator of functional angiogenic responses to VEGFA. We found that SDC4 resides at endothelial cell junctions, interacts with vascular endothelial cadherin, and is required for its internalization in response to VEGFA. Finally, we show that pathological angiogenic responses are inhibited in a model of wet age-related macular degeneration by targeting SDC4. Conclusions: We show that SDC4 is a downstream mediator of VEGFA-induced vascular endothelial cadherin internalization during pathological angiogenesis and a potential target for antiangiogenic therapies.
No takes yet. Share an insight, caveat, or question.
Rossi et al. (2021) studied Pathological angiogenesis (diabetic retinopathy, wet age-related macular degeneration, and tumor development). Syndecan-4 (SDC4) deletion or targeting vs. Wild-type / untargeted controls was evaluated on Pathological angiogenesis and VEGFA-induced VE-cadherin internalization. Targeting syndecan-4 (SDC4) impaired VEGFA-induced VE-cadherin internalization and inhibited pathological angiogenesis in preclinical models of neovascular eye disease and tumor growth.
Synapse has enriched 10 related papers. Consider them for comparative context: